CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

von Tresckow Julia; Cramer Paula; Bahlo Jasmin; Robrecht Sandra; Engelke Anja; Langerbeins Petra; Fink Anna-Maria; Illmer Thomas; Klaproth Holger; Estenfelder Sven; Ritgen Matthias; Fischer Kirsten; Wendtner Clemens-Martin; Kreuzer Karl-Anton; Stilgenbauer Stephan; Bottcher Sebastian; Eichhorst Barbara; Hallek Michael

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

【24h】

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

机译：CLL2-BIG - 一种新型的弯曲蛋白治疗方案，然后是GA101和Ibrutinib，慢性淋巴细胞白血病（CLL）患者中的伊布勒替尼和GA101维持：II期 - 试验的结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology 》 |2016年第22期| 共8页
作者
von Tresckow Julia; Cramer Paula; Bahlo Jasmin; Robrecht Sandra; Engelke Anja; Langerbeins Petra; Fink Anna-Maria; Illmer Thomas; Klaproth Holger; Estenfelder Sven; Ritgen Matthias; Fischer Kirsten; Wendtner Clemens-Martin; Kreuzer Karl-Anton; Stilgenbauer Stephan; Bottcher Sebastian; Eichhorst Barbara; Hallek Michael;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病 ;
关键词

相似文献

外文文献
专利

1. CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial [J] . von Tresckow Julia, Cramer Paula, Bahlo Jasmin, Blood: The Journal of the American Society of Hematology . 2016 ,第22期

机译：CLL2-BIG - 一种新型的弯曲蛋白治疗方案，然后是GA101和Ibrutinib，慢性淋巴细胞白血病（CLL）患者中的伊布勒替尼和GA101维持：II期 - 试验的结果
2. Ibrutinib versus placebo in patients with asymptomatic, treatment-naive early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial [J] . Langerbeins Petra, Bahlo Jasmin, Rhein Christina, Leukemia and lymphoma . 2020 ,第S1期

机译：Ibrutinib与安慰剂在无症状，治疗幼稚早期慢性淋巴细胞白血病（CLL）：第3期双盲随机CLL12试验的主要终点结果
3. Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE [J] . Moreno Carol, Greil Richard, Demirkan Fatih, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：Ibrutinib Plus obinutuzumab与氯苯脲加上obinutuzumab作为慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者的一线治疗（CLL / SLL）：第3阶段照射的结果
4. Chronic Lymphocytic Leukemia (CLL): New Insight on the Pathogenesis of CLL Cell Survival [C] . L. Lagneaux, A. Delforge, M. Dejeneffe, European Haematology Association . 2002

机译：慢性淋巴细胞白血病（CLL）：对CLL细胞生存发病机制的新见解
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter open-label phase II trial (CLL2-BIO) [O] . Paula Cramer, Julia von Tresckow, Sandra Robrecht, 2021

机译：Bendamustine然后是慢性淋巴细胞白血病中的ofatumumab和伊布勒替尼：多中心的主要终点分析开放标签II期试验（CLL2-BIO）
7. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial [O] . 2020

机译：Bendamustine，其次是慢性淋巴细胞白血病（CLL2-BIO）的奥塔姆巴布和伊布洛替尼：多期一位，开放标签阶段试验的主要终点分析

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

著录项

相似文献

相关主题

期刊订阅